source
- Endeavor BioMedicines reports positive phase 2b results for Hedgehog inhibitor taladegib in IPFEndeavor BioMedicines announced that its Hedgehog pathway inhibitor, taladegib, produced encouraging results in a phase 2b study of patients with idiopathic pulmonary fibrosis (IPF). The trial, nam…
- Iambic Therapeutics targets $135M IPO to fund clinical trials of HER2 and KIF18A cancer drugsIambic Therapeutics, a San Diego AI‑driven biotech, filed to raise $135 million in net proceeds through an initial public offering. The company plans to sell 9.4 million shares at $15 to $17 each,…